Startups
Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs.
Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.
Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies. We are guided by our conviction in people, products and breakthrough ideas, not by conventional categories.
Our investments span a variety of instruments from early venture rounds, to late-stage investing, direct secondary transactions, as well as company founding and creation.
Omega Funds has raised more than $1 billion since its inception in 2004 and is headquartered in Boston, Massachusetts, USA.
Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.
Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies. We are guided by our conviction in people, products and breakthrough ideas, not by conventional categories.
Our investments span a variety of instruments from early venture rounds, to late-stage investing, direct secondary transactions, as well as company founding and creation.
Omega Funds has raised more than $1 billion since its inception in 2004 and is headquartered in Boston, Massachusetts, USA.
Overview
Location
United States, Massachusetts, Boston
Employees
11-50
Total raised
$438M
Founded date
2004
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 29
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 7, 2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| Nov 15, 2024 | The Surge of Innovation: Beta Bionics and PMWeb Secure Major Investments | In the fast-paced world of technology and healthcare, two companies have recently made headlines by securing significant funding. Beta Bionics and PMWeb are not just raising capital; they are paving the way for transformative solutions in d... |
| Nov 15, 2024 | Beta Bionics Closes $60M Series E Financing | Beta Bionics, an Irvine, CA-based company which specializes in the development of advanced diabetes management solutions, raised $60M in Series E funding. The round was led by Wellington Management. Previous investors Eventide Asset Managem... |
| Dec 11, 2019 | Venture capital firm Omega Funds closes $438M Fund VI | “We believe this is the most exciting time to be investing in life sciences in a generation, but it requires diverse skills to capture the opportunity set,” Omega Managing Director Otello Stampacchia said in a statement. “At Omega, we have ... |
| Dec 11, 2019 | Top tech startup news for today, Wednesday, December 11, 2019 – Disney, Omega Funds, Perfect Day, LeanDNA, Zero Card, and Aeva | Good morning! Below are some of the top tech startup news for today, Wednesday, December 11, 2019. Disney+ passes 22 million downloads on mobile devices, says app tracking firm Apptopia. Disney, the world’s most popular amusement parks, fl... |
| Dec 11, 2019 | Omega Funds closes $438M for its Fund VI to invest in life sciences startups | Omega Funds, a global life sciences-based investment firm that creates and invests in life sciences companies that target our world’s most urgent medical needs, has closed $438 million in capital commitments for its Omega Fund VI. With Fund... |
| Dec 11, 2019 | Omega Funds Raises $438 Million in Sixth Fund | BOSTON--(BUSINESS WIRE)--Omega Funds, a leading international investment firm focused on delivering impactful medicines to patients, today announced the closing of Omega Fund VI, L.P., with $438 million in capital commitments. With Fund VI,... |
| Mar 21, 2019 | Greenspring Associates Joins $40M Series B for Imago Biosciences | SAN FRANCISCO–(BUSINESS WIRE)–Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds, a leading internationa... |
| Jun 14, 2018 | Andrew Alliance raises $14 million in series C round |
Show more